|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Medical expenditures for colorectal cancer diagnosis and treatment: A 10-year high-level-hospital-based multicenter retrospective survey in China, 2002-2011显示文摘Objective: Colorectal cancer(CRC) causes a substantial burden of disease in China and the evidence of economic burden triggered is fundamental for priority setting. The aim of this survey was to quantify medical expenditures and the time trends for CRC diagnosis and treatment in China.Methods: From 2012 to 2014, a hospital-based multicenter retrospective survey was conducted in 13 provinces across China. For each eligible CRC patient diagnosed from 2002 to 2011, clinical information and expenditure data were extracted using a uniform questionnaire. All expenditure data were reported in Chinese Yuan(CNY)using 2011 values.Results: Of the 14,536 CRC patients included, the average age at diagnosis was 58.2 years and 15.8% were stageI cases. The average medical expenditure per patient was estimated at 37,902 CNY [95 % confidence interval(95%CI): 37,282-38,522], and the annual average increase rate was 9.2% from 2002 to 2011(P for trend <0.001), with a cumulative increase of 2.4 times(from 23,275 CNY to 56,010 CNY). The expenditure per patient in stages Ⅰ, Ⅱ, Ⅲ and Ⅳ were 31,698 CNY, 37,067 CNY, 38,918 CNY and 42,614 CNY, respectively(P<0.001). Expenditure significantly differed within various subgroups. Expenses for drugs contributed the largest proportion(52.6%).Conclusions: These conservative estimates illustrated that medical expenditures for CRC diagnosis and treatment in tertiary hospitals in China were substantial and increased rapidly over the 10 years, with drugs continually being the main expense by 2011. Relatively, medical expenditures are lower for CRC in the earlier stages. These findings will facilitate the economic evaluation of CRC prevention and control in China. | Jufang Shi Guoxiang Liu Hong Wang Ayan Mao Chengcheng Liu Lanwei Guo Huiyao Huang Jiansong Ren Xianzhen Liao Yana Bai Xiaojie Sun Xinyu Zhu Jialin Wang Bingbing Song Jinyi Zhou Lin Zhu Haike Lei Yuqin Liu Yunyong Liu Lingbin Du Yutong He Kai Zhang Ni Li Wanqing Chen Min Dai Jie He | 2019 | Chinese Journal of Cancer Research2019，31，5： | 8 |
| 2 | No expenditure difference among patients with liver cancer at stageⅠ-ⅣV:Findings from a multicenter cross-sectional study in China显示文摘Objective:The number of liver cancer patients in China accounts for more than half of the world.However,China currently lacks national,multicenter economic burden data,and meanwhile,measuring the differences among different subgroups will be informative to formulate corresponding policies in liver cancer control.Thus,the aim of the study was to measure the economic burden of liver cancer by various subgroups.Methods:A hospital-based,multicenter and cross-sectional survey was conducted during 2012・2014,covering 39 hospitals and 21 project sites in 13 provinces across China.The questionnaire covers clinical information,sociology,expenditure,and related variables.All expenditure data were reported in Chinese Yuan(CNY)using 2014 values.Results:A total of 2,223 liver cancer patients were enrolled,of whom 59.61%were late-stage cases(III-IV),and 53.8%were hepatocellular carcinoma.The average total expenditure per liver cancer patient was estimated as 53,220 CNY,including 48,612 CNY of medical expenditures(91.3%)and 4,608 CNY of non-medical expenditures(8.7%).The average total expenditures in stage I,H,m and stage IV were 52,817 CNY,50,877 CNY,50,678 CNY and 54,089 CNY(P>0.05),respectively.Non-medical expenditures including additional meals,additional nutrition care,transportation,accommodation and hired informal nursing were 1,453 CNY,839 CNY,946 CNY,679 CNY and 200 CNY,respectively.The one-year out-of-pocket expenditure of a newly diagnosed patient was 24,953 CNY,and 77.2%of the patients suffered an unmanageable financial burden.Multivariate analysis showed that overall expenditure differed in almost all subgroups(P<0.05),except for sex,clinical stage,and pathologic type.Conclusions:There was no difference in treatment expenditure for liver cancer patients at different clinical stages,which suggests that maintaining efforts on treatment efficacy improvement is important but not enough.To fiirtherly reduce the overall economic burden from liver cancer,more effort should be given to primary and secondary prevention strategies. | Haike Lei Lin Lei Jufang Shi Yongzhong Wu Ling Liang Huiyao Huang Mei He Fangzhou Bai Maomao Cao Hui Qiu Yuting Wang Chengcheng Liu Jia Du Hong Wang Yan Zhang Mengdi Cao Ji Peng Ni Li Chunfeng Qu Min Dai Wanqing Chen Jie He | 2020 | Chinese Journal of Cancer Research2020，32，4： | 7 |
| 3 | Classifying risk level of gastric cancer: Evaluation of questionnaire-based prediction model显示文摘Objective: This study aimed at evaluating the efficacy of the questionnaire-based prediction model in an independent prospective cohort.Methods: A cluster-randomized controlled trial was conducted in Changsha, Harbin, Luoshan, and Sheyang in eastern China in 2015-2017. A total of 182 villages/communities were regarded as clusters, and allocated to screening arm or control arm randomly. Face-to-face interview through a questionnaire interview, including of relevant risk factors of gastric cancer, was administered for each subject. Participants were further classified into high-risk or low-risk groups based on their exposure to risk factors. All participants were followed up until December 31, 2019. Cumulative incidence rates from gastric cancer between high-risk and low-risk groups were calculated and compared using the log-rank test. Cox proportional hazard regression models were applied to estimate hazard ratio(HR) and 95% confidence interval(95% CI).Results: Totally, 89,914 residents were recruited with a mean follow-up of 3.47 years. And 42,015(46.73%)individuals were classified into high-risk group and 47,899(53.27%) subjects were categorized into low-risk group.Gastric cancer was diagnosed in 131 participants, of which 91 were in high-risk group. Compared with the low-risk participants, high-risk individuals were more likely to develop gastric cancer(adjusted HR=2.15, 95% CI,1.23-3.76). The sensitivity of the questionnaire-based model was estimated at 61.82%(95% CI, 47.71-74.28) in a general population.Conclusions: Our questionnaire-based model is effective at identifying high-risk individuals for gastric cancer. | Maomao Cao He Li Dianqin Sun Lin Lei Jiansong Ren Jufang Shi Ni Li Ji Peng Wanqing Chen | 2020 | Chinese Journal of Cancer Research2020，32，5： | 5 |
| 4 | LabVIEW-based auto-timing counts virtual instrument system with ORTEC 974 Counter/Timer显示文摘In order to achieve the auto-timing counts measurement of nuclear radiation using ORTEC 974 Counter/Timer, an auto-timing counts virtual instrument system based on the LabVIEW virtual instrument development platform and GPIB instrument control and transmission bus protocol is designed in this paper. By introducing software timing technique, the minimum time base of factory setting improves from 0.1 s to 0.03 s. The timing counts performance and longtime stability are also discussed in detail. The automatic data recording and saving facilitates data analysis and processing. Its real-time display and statistic function is very convenient for monitoring the nuclear radiation. | YAN Jie LIU Rong LI Cheng JIANG Li LU Xinxin ZHU Tonghua WANG Mei WEN Zhongwei LIN Jufang | 2009 | Nuclear Science and Techniques2009，20，5： | 2 |
| 5 | Generation of sp3111 transgenic RNAi mice via permanent integration of small hairpin RNAs in repopulating spermatogonial cells in vivo显示文摘spermatid 特定的基因, sp3111,是 four-transmembrane 基因家庭的一个新成员。然而,它的繁殖生物功能留下逃犯。这研究的目的是为进一步在它的繁殖功能上学习 sp3111 基因表示的抑制的效果建立一个 sp3111 击倒的雄的老鼠模型。pSUPER-sp3111-shRNA 的 Recombinant 向量,对老鼠 sp3111 mRNA 的不同区域包含抄录功能的小发卡 RNA 顺序,被构造并且识别。然后,线性化的 recombinant 向量被 electroporation 注入成熟老鼠睾丸和 transfected 到 spermatogonial 房间产生 sp3111 转基因的 RNAi 老鼠。这些 electroporated 男性老鼠与野类型的女性一起被交配在 electroporation 和他们的子孙以后的 30 天被荧光显微镜学和 PCR 两个都检验。在 vivo 的 sp3111 mRNA 的睾丸表达式上的 RNAi 的抑制效率是超过30%并且能稳定地被传给 F3 产生,这被发现,并且与野类型的雄的鼠标相比,吗 sp3111 RNAi 雄的鼠标的后代的吝啬的数字从 11 被减少???????????????????????栠吗?? | Weili Shi Tingyan Shi Zheyu Chen Jufang Lin Xiaofeng Jia Jian Wang Huijuan Shi | 2010 | Acta Biochimica et Biophysica Sinica2010，42，2： | 2 |
| 6 | 3-75 Radiosensitizing Effects of miR-185 on Melanoma Cells显示文摘Melanoma is an aggressive malignancy with high metastasis and low survival rate, of which the incidence rate keeps increasing year by year worldwide while the therapeutic options are still limited up to now[1;2]. Melanoma is considered to be a relatively radioresistant tumor, and radiotherapy has an important role in its treatment, especially in patients with central nervous system metastases[3], so enhancement of cellular radiosensitivity by radiosensitizer is an efficient strategy to improve the outcome of radiotherapy. | He Jinpeng Tian Ning Yang Yanli Jin Liangliang Feng Xiu Hua Junrui Lin Sulan Wang Bing Li He Wang Jufang | 2015 | IMP & HIRFL Annual Report2015，，1： | 0 |
| 7 | Inappropriate Activation of TLR4/NF-κB is a Cause of Heart Failure显示文摘Significance:Heart failure,a disease with extremely high incidence,is closely associated with inflammation and oxidative stress.The Toll-like receptor 4(TLR4)/nuclear factor kappa-B(NF-κB)pathway plays an important role in the occurrence and development of heart failure.Recent advances:Previous studies have shown that TLR4/NF-κB causes heart failure by inducing oxidative stress and inflammation;damaging the endothelia;promoting fibrosis;and inducing myocardial hypertrophy,apoptosis,pyroptosis,and autophagy.Critical issues:Understanding the pathogenesis of heart failure is essential for the treatment of this disease.In this review,we outline the mechanisms underlying TLR4/NF-κB pathway-mediated heart failure and discuss drugs that alleviate heart failure by regulating the TLR4/NF-κB pathway.Future directions:During TLR4/NF-κB overactivation,interventions targeting specific receptor antagonists may effectively alleviate heart failure,thus providing a basis for the development of new anti-heart failure drugs. | Jiedong Zhou Hui Lin Tingting Lv Jinjin Hao Hanlin Zhang Shimin Sun Juntao Yang Jufang Chi Hangyuan Guo | 2022 | Cardiovascular Innovations and Applications2022，7，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员